Clio P Mavragani
Overview
Explore the profile of Clio P Mavragani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
2029
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skarlis C, Papadopoulos V, Raftopoulou S, Mavragani C, Evangelopoulos M
J Neurol Sci
. 2024 May;
461:123046.
PMID: 38761670
Introduction: Progressive multifocal leukoencephalopathy (PML) is a potentially life-threatening complication among Multiple Sclerosis (MS) patients under natalizumab treatment, with serum anti-JCV antibody titers being used for stratification risk. Given the...
2.
Fragoulis G, Ntouros P, Nezos A, Vlachogiannis N, McInnes I, Tektonidou M, et al.
Front Immunol
. 2023 Dec;
14:1274060.
PMID: 38124740
Objectives: The abnormal DNA damage response is associated with upregulation of the type-1 interferon (IFN-I) pathway in certain rheumatic diseases. We investigated whether such aberrant mechanisms operate in psoriatic arthritis...
3.
Skarlis C, Papadopoulos V, Raftopoulou S, Mavragani C, Evangelopoulos M
Clin Immunol
. 2023 Nov;
257:109847.
PMID: 37995946
Although B cells and B cell activating factor (BAFF) have been previously implicated in MS pathogenesis, data regarding the genetic influence of BAFF polymorphisms on MS susceptibility are limited. Here...
4.
Marketos N, Mavragani C
Mediterr J Rheumatol
. 2023 Nov;
34(3):398-402.
PMID: 37941855
Introduction: Previous studies have revealed the presence of anticentromere antibodies in patients with Sjögren's syndrome (SS), predominantly in those serologically negative for antibodies against Ro/SSA and La/SSB antigens (seronegative). The...
5.
Markousis-Mavrogenis G, Belegrinos A, Giannakopoulou A, Papavasiliou A, Koulouri V, Marketos N, et al.
J Clin Med
. 2023 Feb;
12(4).
PMID: 36836108
Introduction: Myopathies are heterogeneous neuromuscular diseases of genetic and/or inflammatory etiology that affect both cardiac and skeletal muscle. We investigated the prevalence of cardiac inflammation in patients with myopathies, cardiovascular...
6.
Koulouri V, Bakasis A, Marketos N, Tavernaraki K, Giannelou M, Moutsopoulos H, et al.
J Transl Autoimmun
. 2023 Jan;
6:100183.
PMID: 36619654
Systemic sclerosis (SSc) has been classically linked to interstitial lung disease (ILD) development, often in association with specific SSc autoantibodies. In the present report, we aimed to estimate the prevalence...
7.
Marketos N, Mavragani C
Semin Arthritis Rheum
. 2022 Dec;
58:152156.
PMID: 36580853
No abstract available.
8.
Bellos S, Velonakis G, Anagnostouli M, Mavragani C, Evangelopoulos M
Clin Exp Rheumatol
. 2022 Nov;
40(12):2468-2469.
PMID: 36441647
No abstract available.
9.
Raftopoulou S, Rapti A, Karathanasis D, Evangelopoulos M, Mavragani C
Front Neurol
. 2022 Nov;
13:1026449.
PMID: 36438941
Type I interferons (IFNs) are major mediators of innate immunity, with well-known antiviral, antiproliferative, and immunomodulatory properties. A growing body of evidence suggests the involvement of type I IFNs in...
10.
Mavragani C, Kirou K, Seshan S, Crow M
Rheumatology (Oxford)
. 2022 Nov;
62(7):2534-2538.
PMID: 36355567
Objectives: To investigate the expression of type I IFN (IFN-I) and neutrophil transcripts in kidney tissue from patients with different classes of LN and their association with distinct clinical and...